Something in the blood? A history of the autoimmune hypothesis regarding myasthenia gravis

Journal of the History of the Neurosciences

Volumn 16, Issue 4, 2007, Pages 395-412

  Keesey, John ^a,c   Aarli, Johan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

^c NONE   (United States)

Author keywords

Acetylcholine receptor; Autoimmune; Circulating factor; Complement; Muscle antibodies; Myasthenia gravis; Thymus antibodies; Witebsky postulates

Indexed keywords

ATROPINE; COMPLEMENT; IMMUNOSUPPRESSIVE AGENT; MUSCLE ANTIBODY; NEOSTIGMINE; PHYSOSTIGMINE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLOOD LEVEL; CELLULAR IMMUNITY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; IMMUNOBIOLOGY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NEWBORN DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; REVIEW; SKELETAL MUSCLE; THYMOMA; THYMUS; TREATMENT RESPONSE;

AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; RISK FACTORS; THYMUS GLAND;

EID: 35648950009     PISSN: 0964704X     EISSN: 17445213     Source Type: Journal    
DOI: 10.1080/09647040600675322     Document Type: Review

References (125)

1. Aarli JA, Stefansson K, Marton LS, Wollmann RL (1990): Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 82: 284-288.
2. Bergh NP (1953): Biological assays in myasthenia gravis for any agents causing a neuromuscular block. Scand J Clin Lab Invest 5 (Suppl 5): 1-47.
3. Beutner EB, Witebsky E, Ricken D, Adler RH (1962): Studies on autoantibodies in myasthenia gravis. JAMA 182: 156-168.
4. Blalock A, Harvey AM, Ford FF, Lilienthal JL (1941): The treatment of myasthenia gravis by removal of the thymus gland. JAMA 117: 1529-1533.
5. Brooks J (1971): Discussion. Res Pub Assoc Res Nerv Ment Dis 49:253-257.
6. Buckley GA, Roberts DV, Roberts JB, Thomas BH, Wilson A (1968): Drug-induced neonatal myasthenia. Brit J Parmacol 34: 203P-204P.
7. Burnet FM (1959): The Clonal Selection Theory of Acquired Immunity. Cambridge, Cambridge University Press.
8. Burnet FM, Mackay IR (1962): Lymphoepithelial structures and autoimmune disease. Lancet 2:1030-1033.
9. Buzzard EF (1905): The clinical history and post-mortem examination of five cases of myasthenia gravis. Brain 28: 438-483.
10. Campbell H, Bramwell E (1900): Myasthenia gravis. Brain 23: 277-336.
11. Castleman B (1955): Tumors of the Thymus Gland. Fascicle 19. Atlas of Tumor Pathology. Armed Forces Institute of Pathology, Washington, DC, p. 15.
12. Coons AH (1961): The beginnings of immunofluorescence. J Immunology 87: 499-503.
13. Dameshek W, Schwartz SO (1940): Acute hemolytic anemia (acquired hemolytic icterus, acute type). Medicine 19: 231-327.
14. Dausset J, Nenna A, Brecy H (1954): Leukoagglutinins V. Leukoagglutinins in chronic idiopathic or symptomatic pancytopenia and in paroxysmal nocturnal hemoglobinuria. Blood 9: 696-720.
15. Dixon FJ (1958): Autoimmunity in disease. Ann Rev Med 9: 257-286.
16. Donath J, Landsteiner K (1904): Ueber paroxysmale haemoglobinurie. Münch. Med. Wochenschr 51: 1590-1593.
17. Ehrlich P (1897): Die Wertbemessung des Diphtherieheilserums. Klin. Jahrb 60: 299.
18. Ehrlich P (1901): Die Schutzstoffe des Blutes. Verhandlungen 73 Ges. Deutsche Naturforschung Ärzte 1: 250-275.
19. Epstein RD, Lozner EL, Cobbey TS, Davidson CS (1950): Congenital thrombocytopenic purpura. Purpura hemorrhagica in pregnancy and the newborn. Amer J Med 9: 44-56.
20. Erb W (1879): Sur Casuistik der bulbären Lähmungen. Archiv für Psychiatrie und Nervenkrankheiten 9: 336-350.
21. Fambrough DM, Drachman DB, Satyamurti S (1973): Neuromuscular junction in myasthenia gravis; decreased acetylcholine receptors. Science 182: 193-195.
22. Gitlin D, Kumate J, Urrusti J, Morales C (1964): The selectivity of the human placenta in the transfer of plasma proteins from mother to fetus. J Clin Invest 43: 1938-1951.
23. Goldflam S (1893): Ueber einen scheinbar heilbaren bulbä rparalytischen Symptomencomplex mit Betheiligung der Extremitäten. Deutsche Zeitschrift für Nervenheilkunde 4: 312-352.
24. Goldstein G (1966): Thymitis and myasthenia gravis. Lancet 2: 1164-1167.
25. Goldstein G (1968): The thymus and neuromuscular function. A substance in thymus which causes myositis and myasthenic neuromuscular block in guinea pigs. Lancet 2: 119-122.
26. Goldstein G, Hofmann WW (1968): Electrophysiological changes similar to those of myasthenia gravis in rats with experimental autoimmune thymitis. J Neurol Neurosurg Psychiat 1968 31: 453-459.
27. Goldstein G, Whittingham S (1967): Histological and serological features of experimental autoimmune thymitis in guinea pigs. Clin Exp Immunol 2: 257-268.
28. Greene R (1950): The significance of lymphadenoid changes in the thyroid gland. J Endocrinology 7: 1-10.
29. Grob D, Johns RJ, Harvey AM (1956): Studies in neuromuscular function VI. Effects of anticholinesterase compounds, d-tubocurarine, and decamethonium in patients with myasthenia gravis. Bull Johns Hopkins Hospital 99: 195-238.
30. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV (1951): Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenia purpura. J Lab Clin Med 38: 1-10.
31. Harvey AM, Masland RL (1941): The electromyogram in myasthenia gravis. Bull Johns Hopkins Hospital 69: 1-13.
32. Harvey AM, Shulman LE, Tumulty PA, Conley CL, Schoenrich EH (1954): Systemic lupus erythematosus: Review of the literature and clinical analysis of 138 cases. Medicine 33: 291-437.
33. Henry K (1966): Mucin secretion and striated muscle in the human thymus. Lancet 1: 183-185.
34. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001): Auto- antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7: 365-368.
35. Holman HR, Kunkel HG (1957): Affinity between the lupus erythematosus serum factor and cell nuclei and nucleoprotein. Science 126: 162-163.
36. Hoppe HH (1892): Ein Beitrag zur Kenntniss der Bulbar-Paralyse. Berliner Klinische Wochenschrift 29: 332-336.
37. Jolly F (1895): Ueber Myasthenia gravis pseudoparalytica. Berliner Klinische Wochenschrift 32: 1-7.
38. Jones SF, Brennan JL, McLeod JG (1971): An investigation of experimental myasthenia gravis. J Neurolo Neurosurg Psychiat 34: 399-403.
39. Kalden JR, Williamson WG, Johnston RJ, Irvine WJ (1969): Studies on experimental autoimmune thymitis in guinea-pigs. Clin Exp Immunol 5: 319-340.
40. Keesey J (1998): Contemporary opinions about Mary Walker, a shy pioneer of therapeutic neurology. Neurology 51: 1433-1439.
41. Keesey J (2002): Myasthenia Gravis, An Illustrated History. Roseville, Publishers Design Group.
42. Keesey J (2003): The Role of Herman Hoppe of Cincinnati in the Clinical Recognition of Myasthenia Gravis. J Hist Neurosciences 12: 167-174.
43. Keesey J (2004a): A history of treatments for myasthenia gravis. Seminars in Neurology 24: 5-16.
44. Keesey J (2004b): Clinical evaluation and management of myasthenia gravis. Muscle & Nerve 29: 484-505.
45. Keesey J (2005): How electric fish became sources of acetylcholine receptor. J Hist Neurosci 14: 1-16.
46. Keynes G (1952): Obstetrics and gynaecology in relation to thyrotoxicosis and myasthenia gravis. J Obstet Gynaec Brit Emp 59: 173-182.
47. Kuhn TS (1962): The Structure of Scientific Revolutions. Chicago, University of Chicago Press.
48. Lauriola L, Ranelletti F, Maggiano N, Guerriero M, Punzi C, Marsili F, Bartoccini E, Evoli A (2005): Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 64: 536-538.
49. Lennon V, Lindstrom J, Seybold M (1975): Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs. J Exp Med 141: 1365-1375.
50. Levin PM (1949): Congenital myasthenia in siblings. Arch Neurol Psychiat 62: 745-758.
51. Lindstrom JM (2004): Is "seronegative" MG explained by autoantibodies to MuSK? Neurology 62: 1920-1921.
52. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1976): Antibody to acetylcholine receptor in myasthenia gravis. Neurology 26: 1054-1059.
53. Mackay IR, Burnet FM (1963): Autoimmune Disease, Pathogenesis, Chemistry and Therapy. Springfield, IL, CC Thomas.
54. Marshall AHE, White RG (1961): The immunological reactivity of the thymus. Brit J Exper Path 42: 379-385.
55. Mayer S (1888): Zur Lehre von der Schilddrüse und Thymus bei den Amphibien. Anatomischer Anzeiger 3: 97-103.
56. McFarlin DE, Engel WK, Strauss AJL (1966): Does myasthenic serum bind to the neuromuscular junction? Ann NY Acad Sci 135: 657-663.
57. rd edition.
58. Miller JFAP (1961): Immunological function of the thymus. Lancet 2: 748-749.
59. Murphy A, Drachman DB, Satya-Murti S, Pestronk A, Eggleston JC (1980): Critical reexamination of the thymus immunization model of myasthenia gravis. Muscle & Nerve 3: 293-297.
60. Nastuk WL (1955): Neuromuscular transmission, fundamental aspects of the normal process. Am J Med 19: 663-668.
61. Nastuk WL, Osserman KE, Plescia OJ (1956): Reduction in serum complement concentration in myasthenia gravis. Fed Proc 15: 135-136.
62. Nastuk WL, Plescia OJ (1966): Current status of research on myasthenia gravis. Ann NY Acad Sci 135: 664-678.
63. Nastuk WL, Plescia OJ, Osserman KE (1960): Changes in serum complement activity in patients with myasthenia gravis. Proc Soc Exper Biol Med 105: 177-184.
64. Nastuk WL, Strauss AJL (1961): Further developments in the search for a neuromuscular blocking agent in the blood of patients with myasthenia gravis. In: Viets HR, ed., Myasthenia Gravis, the Second International Symposium Proceedings. Springfield, IL, Charles C. Thomas.
65. Nastuk WL, Strauss AJL, Osserman KE (1959): Search for a neuromuscular blocking agent in the blood of patients with myasthenia gravis. Am J Med 26: 394-409.
66. Nilsby I (1949): Myasthenia gravis of a newborn child. Acta Paediat 37: 489-492.
67. Oosterhuis HJGH, Feltkamp TEW, van der Geld HRW (1966): Muscle antibodies in myasthenic mothers and their babies. Lancet 2: 1226-1227.
68. Oppenheim H (1887): Ueber einen Fall von chronischer progressiver Bulbarparalyse ohne anatomischen Befund. Virchow's Archiv für pathologische Anatomie und Physiologie und für klinische Medicin 108: 522-530.
69. Osserman KE (1966): ed. Myasthenia Gravis. Ann NY Acad Sci 1966 135: 683.
70. Patrick J, Lindstrom J (1973). Autoimmune response to acetylcholine receptor. Science 180: 871-872.
71. Peterson OH, Larson P (1954): Thrombocytopenic purpura in pregnancy. Obstet Gynec 4: 454-469.
72. Rivers TM, Sprunt DH, Berry GP (1933): Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exper Med 58: 39-54.
73. Robson HN, Davidson LS (1950): Purpura in pregnancy, with special reference to idiopathic thrombocytopenic purpura. Lancet 2: 164-169.
74. Roitt IM, Doniach D, Campbell PN, Hudson RV (1956): Auto-antibodies in Hashimoto's disease (lymphadenoid goiter). Lancet 2: 820-821.
75. Rose HM, Ragan C, Pearce E, Lipman MO (1948): Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exper Biol Med 68: 1-6.
76. Rose NR, Bona C (1993): Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunology Today 14: 426-430.
77. Rose NR, Mackay IR (1985): The Autoimmune Diseases. Orlando, FL, Academic Press Inc., p. xxxiv.
78. Rose NR, Witebsky E (1956): Studies on organ specificity V. Changes in the thyroid glands of rabbits following active immunization with rabbit thyroid extracts. J Immunology 76: 417-426.
79. Russell DS (1953): Histological changes in the striped muscles in myasthenia gravis. J Path Bacteriol 65: 279-289.
80. Schumacher CH, Roth P (1913): Thymektomie bei einem Fall von Morbus Basedowi mit Myasthenia. Mitteilungen aus den Grenzgebieten der Medizin und Chirurgie 25: 746-765.
81. Schwarz H (1952): Curare-like factor in serum of myasthenia gravis patients. Canada Med Assn J 67: 238-244.
82. Scott JS (1966): Immunological disease and pregnancy. Brit Med J 1: 1559-1567.
83. Silverstein AM (1989): A History of Immunology. New York: Academic Press, Inc.
84. Silverstein AM (1991): The dynamics of conceptual change in twentieth century immunology. Cell Immunol 132: 515-531.
85. Silverstein AM (2001): Autoimmunity versus horror autotoxicus: The struggle for recognition. Nature Immunology 4: 279-281.
86. Silverstein AM (2002): The clonal selection theory: What it really is and why modern challenges are misplaced. Nature Immunol 3: 793-796.
87. Simpson JA (1958): An evaluation of thymectomy in myasthenia gravis. Brain 81: 112-144.
88. Simpson JA (1960): Myasthenia gravis: A new hypothesis. Scot Med J 5: 419-436.
89. Simpson JA (1977): Myasthenia gravis - Validation of a hypothesis. Scot Med J 22: 201-210.
90. Sloan HE (1943): The thymus in myasthenia gravis with observations on the normal anatomy and histology of the thymus. Surgery 12: 154-174.
91. Smithers DW (1959): Tumours of the thyroid gland in relation to some general concepts of neoplasia. J of the Faculty of Radiologists (Lond) 10: 3-16.
92. Stefanini M, Mele RH (1958): The significance of platelet antibodies, with special reference to platelet agglutinins. Acta Hematol 20: 195-202.
93. Steiner JW, Volpe R (1961): Autoimmunization - A possible mechanism of tissue injury I. Theoretical and experimental aspects. Canad Med Assn J 84: 1165-1172.
94. Strauss AJL (1968): Myasthenia gravis, autoimmunity and the thymus. Adv Int Med 14: 241-280.
95. Strauss AJL, Deitch A, Hsu K (1961): Further observations on the localization of a muscle-binding complement-fixing serum globulin fraction in myasthenia gravis. Fed Proc 20: 38.
96. Strauss AJL, Kemp PG, Douglas SD (1966): Myasthenia gravis. Lancet 1: 772-773.
97. Strauss AJL, Seegal BC, Hsu KC, Burkholder PM, Nastuk WL, Osserman KE (1960): Immunofluorescence demonstration of a muscle binding, complement-fixing serum globulin fraction in myasthenia gravis. Proc Soc Exper Biol Med 105: 184-191.
98. Strauss AJL, Smith CW, Cage WS, Van der Geld HWR, McFarlin DE, Barlow M (1966): Further studies on the specificity of presumed immune associations of myasthenia gravis and consideration of possible pathogenic implications. Ann NY Acad Sci 135: 557-579.
99. Strickroot FL, Schaeffer RL, Bergo HL (1942): Myasthenia gravis occurring in an infant born of a myasthenic mother. JAMA 120: 1207-1209.
100. Taylor KB, Morton JA (1958): An antibody to Castle's intrinsic factor. Lancet 1: 29-30.
101. Teng P, Osserman KE (1956): Studies in myasthenia gravis: Neonatal and juvenile types. J Mt Sinai Hosp 23: 711-727.
102. Torda C, Wolff H (1946): Apparent curare effect of substances that decrease acetylcholine synthesis. Amer J Physiol 147: 384-390.
103. Uhlenhuth L (1903): Zur Lehre von der Unterscheidung verschiedener Eiweissarten mit Hilfe spezifischer Sera. In: Festschrift zum Sechzigsten Geburtstage von Robert Koch. Jena, G. Fischer, pp. 49-74.
104. Van der Geld H, Feltkamp TEW, Oosterhuis HJGH (1964): Reactivity of myasthenia gravis serum gamma-globulin with skeletal muscle and thymus demonstrated by immunofluorescence. Proc Soc Exp Biol Med 115: 782-785.
105. Van der Geld H, Oosterhuis HJGH (1963): Muscle and thymus antibodies in myasthenia gravis. Vox Sang 8: 196-204.
106. Van der Geld HWR, Strauss AJL (1966): Myasthenia gravis, immunological relationship between striated muscle and thymus. Lancet 1: 57-60.
107. Van de Velde RL, Friedman NB (1966): Muscular elements of the thymus. Fed Proc 25: 661.
108. Vaughan JH (1965): Introduction. In: Samter J, ed., Immunological Diseases. London, JA Churchill, pp. 723-724.
109. Vetters JM (1965): Immunofluorescence staining patterns in skeletal muscle using serum of myasthenic patients and normal controls. Immunology 9: 93-95.
110. Vetters JM, Simpson JA, Folkarde A (1969): Experimental Myasthenia Gravis. Lancet 2: 28-31.
111. Viets HR (1961): ed. Myasthenia Gravis, the Second International Symposium Proceedings. Springfield, IL, CC Thomas.
112. von Reis G, Liljestrand Å, Matell G (1966): Treatment of severe myasthenia gravis with large does of ACTH. Ann NY Acad Sci 135: 409-416.
113. Waksman BH (1998): Historical perspective and overview. In: Antel J, Birnbaum G, Hartung HP, eds., Clinical Neuroimmunology. London, Blackwell.
114. Walker MB (1934): Treatment of myasthenia gravis with physostigmine. Lancet 1: 1200-1201.
115. Walker MB (1935): Case showing the effect of Prostigmin on myasthenia gravis. Proc R Soc Med 28: 759-761.
116. Walker MB (1938): Myasthenia gravis: A case in which fatigue of the forearm muscles could induce paralysis of the extra-ocular muscles. Proc R Soc Med 31: 722.
117. Weigert C (1901): Pathologisch-anatomischer Beitrag zur Erb'schen Krankheit (Myasthenia Gravis). Neurologisches Zentralblatt 20: 597-601.
118. Wekerle H (1993): The thymus in myasthenia gravis. Ann NY Acad Sci 681: 46-55.
119. Wilson A, Obrist A, Wilson H (1953): Some effects of extracts of thymus glands removed from patients with myasthenia gravis. Lancet 2: 368-371.
120. Wilson A, Stoner HB (1944): Myasthenia gravis: A consideration of its causation in a study of fourteen cases. Quart J Med new ser 13: 1-18.
121. Witebsky E (1954): Ehrlich's side-chain theory in the light of present immunology. Ann NY Acad Sci 59: 168-181.
122. Witebsky E, Rose NR (1956): Studies on organ specificity IV. Production of rabbit thyroid antibodies in the rabbit. J Immunol 76: 408-416.
123. Witebsky E, Rose NR, Terplan K, Paine JR, Egan RW (1957). Chronic thyroiditis and autoimmunization. JAMA 164: 1439-1447.
124. Wolf SM, Rowland LP, Schotland DL, McKinney AS, Hoefer PRA, Aranow H. (1966): Myasthenia as an autoimmune disease: Clinical aspects. Ann NY Acad Sci 135: 517-534.
125. Zacks SI, Cohen RB (1955): Myasthenia gravis: Importance of potassium in inhibitory action of normal and myasthenic thymus extracts. Proc Soc Exper Biol Med 90: 601-606.